• Policy
• Companies are worried about the result of Godex revaluation
• by Lee, Tak-Sun Jul 13, 2022 06:04am

• Policy
• Hanall Biopharma's Glucofree OR is back
• by Lee, Tak-Sun Jul 12, 2022 05:53am

• Policy
• Reimbursement of new migraine drugs gain momentum
• by Lee, Tak-Sun Jul 11, 2022 06:04am

• Policy
• ↑Rosuvastatin when combined with Brilinta/Rosuvastatin
• by Lee, Hye-Kyung Jul 11, 2022 06:04am

• Policy
• New Donepezil & a dilemma over low drug prices
• by Lee, Tak-Sun Jul 11, 2022 06:03am

• Policy
• Hemophilia Type A tx, Bayer's Jivi has been approved
• by Lee, Hye-Kyung Jul 10, 2022 03:35pm

• Policy
• The MFDS announced the designation of 4 temporary narcotics
• by Lee, Hye-Kyung Jul 7, 2022 05:54am

• Policy
• Antiepileptic perampanel’s adverse event rate at 32%
• by Lee, Hye-Kyung Jul 5, 2022 05:59am

• Policy
• The revaluation of Streptokinase could be maintained for 1yr
• by Lee, Tak-Sun Jul 5, 2022 05:59am

• Policy
• Support for online conferences will be extended for 1 yr
• by Kim, Jung-Ju Jul 5, 2022 05:58am